Bafna Pharmaceuticals Ltd
NSE:BAFNAPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Bafna Pharmaceuticals Ltd
Cash from Operating Activities
Bafna Pharmaceuticals Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bafna Pharmaceuticals Ltd
NSE:BAFNAPH
|
Cash from Operating Activities
₹154.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Cash from Operating Activities
₹58.8B
|
CAGR 3-Years
12%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Cash from Operating Activities
₹42.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Cash from Operating Activities
₹127.2B
|
CAGR 3-Years
46%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Lupin Ltd
NSE:LUPIN
|
Cash from Operating Activities
₹47.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
146%
|
CAGR 10-Years
N/A
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Cash from Operating Activities
₹19.4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
Bafna Pharmaceuticals Ltd
Glance View
Bafna Pharmaceuticals Ltd. engages in the manufacture of drugs and medicines of life saving drugs. The company is headquartered in Chennai, Tamil Nadu. The company went IPO on 2008-06-27. The firm is manufacturing over 336 licensed pharmaceutical formulations and has globally registered approximately 78 of its products. The firm caters to both domestic and international markets. The firm has two manufacturing facilities in Chennai. Its Madhavram facility manufactures finished solid oral and liquid oral dosage forms of Betalactam and Non-Betalactam and Cephalosporin products. The firm supplies its finished products to countries including Sri Lanka, Ghana, Ukraine, and Laos. The firm's subsidary include Bafna Lifestyles Remedies Limited.
See Also
What is Bafna Pharmaceuticals Ltd's Cash from Operating Activities?
Cash from Operating Activities
154.4m
INR
Based on the financial report for Dec 31, 2025, Bafna Pharmaceuticals Ltd's Cash from Operating Activities amounts to 154.4m INR.
What is Bafna Pharmaceuticals Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 1Y
8%
Over the last year, the Cash from Operating Activities growth was 8%.
